The subsequent EarlyCDT®-Lung ELISA kit, targeting seven TAAs (p53, NY-ESO-1, CAGE, GBU4-5, SOX2, HuD/ELAVL4, and MAGEA4), demonstrated a sensitivity of 41% and a specificity of 91% [10], improving the accuracy of lung cancer nodule assessment when used alongside LDCT [11,12]. This evidence concerns the gene ELAVL4 and lung cancer.